Physician profile
Steven Litz
NPI 1336182013
$3,159.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $387 · 2021: $472 · 2022: $490 · 2023: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $776.25 | 2019-2023 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $748.53 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Kaleo, INC. | $421.69 | 2019-2023 | Auvi-Q |
| Genzyme Corporation | $339.91 | 2019-2023 | |
| Genentech USA, INC. | $254.71 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $213.02 | 2019-2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $161.79 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $92.27 | 2021-2023 | Airduo Digihaler |
| Optinose US, INC. | $79.79 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $16.99 | 2023 | |
| Hikma Pharmaceuticals USA | $15.57 | 2023 | Ryaltris |
| Mdd US Operations, LLC | $14.43 | 2020 | |
| Uswm, LLC | $12.54 | 2021 | |
| Aimmune Therapeutics, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Litz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.